Research programme: cyanoaziridine derivatives - Amplimed

Drug Profile

Research programme: cyanoaziridine derivatives - Amplimed

Alternative Names: AMP423; Cyanoaziridine anti-cancer therapies; Cyanoaziridines

Latest Information Update: 28 Apr 2011

Price : $50

At a glance

  • Originator AmpliMed
  • Class Aziridines; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Apr 2011 Preclinical development is ongoing in USA
  • 06 Apr 2011 Pharmacodynamics data from a preclinical trial in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)
  • 31 May 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top